Holen Sie sich die Stockscreener-App
16.49
2.55%
0.41
Handel nachbörslich:
16.49
Schlusskurs vom Vortag:
$16.08
Offen:
$16.19
24-Stunden-Volumen:
151.10K
Relative Volume:
0.60
Marktkapitalisierung:
$975.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.02M
KGV:
-3.655
EPS:
-4.5116
Netto-Cashflow:
$-152.10M
1W Leistung:
+4.24%
1M Leistung:
+2.81%
6M Leistung:
-3.06%
1J Leistung:
+52.21%
1-Tages-Spanne:
$15.95
$16.61
1-Wochen-Bereich:
$15.04
$17.43
52-Wochen-Spanne:
$8.51
$26.18
Dbv Technologies Adr Stock (DBVT) Company Profile
Firmenname
Dbv Technologies Adr
Sektor
Branche
Telefon
33(0)155427878
Adresse
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
16.49 | 951.72M | 0 | -168.02M | -152.10M | -4.5116 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 126.01B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 70.03B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 56.56B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 40.63B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-12-03 | Eingeleitet | Guggenheim | Buy |
| 2025-05-29 | Fortgesetzt | Goldman | Sell |
| 2023-01-04 | Hochstufung | Societe Generale | Hold → Buy |
| 2022-12-16 | Herabstufung | Goldman | Neutral → Sell |
| 2022-05-10 | Herabstufung | Goldman | Buy → Neutral |
| 2021-09-14 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-01-22 | Herabstufung | Societe Generale | Hold → Sell |
| 2020-11-02 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-08-06 | Herabstufung | Societe Generale | Buy → Sell |
| 2020-08-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-17 | Herabstufung | Stifel | Buy → Hold |
| 2020-01-09 | Hochstufung | Stifel | Hold → Buy |
| 2019-12-16 | Eingeleitet | Citigroup | Buy |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-06-17 | Eingeleitet | Goldman | Buy |
| 2018-12-20 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-12-20 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-12-20 | Herabstufung | Jefferies | Buy → Hold |
| 2018-12-20 | Herabstufung | Stifel | Buy → Hold |
| 2017-10-31 | Hochstufung | Societe Generale | Sell → Hold |
| 2017-10-24 | Herabstufung | Societe Generale | Buy → Sell |
| 2017-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-06-23 | Eingeleitet | Deutsche Bank | Buy |
| 2017-03-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2016-09-26 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-03 | Eingeleitet | Barclays | Overweight |
| 2015-10-23 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Dbv Technologies Adr Aktie (DBVT) Neueste Nachrichten
Europe’s US-Listed ADRs Slipped Late Tuesday Morning - Finimize
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - markets.businessinsider.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
DBV Technologies (NASDAQ: DBVT) targets Q3 2026 for VIASKIN Peanut BLA filing - Stock Titan
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing - The Manila Times
European ADRs Rose As Biopharma Names Led The Pack - Finimize
A40WEX Forecast — Price Target — Prediction for 2027 - TradingView
European ADRs Climb In Thursday U.S. Morning Session: ARGX, PHIA, CRTO In Focus - foreignpolicyjournal.com
European ADRs Rose In US Trading Late Thursday Morning - Finimize
DBV1 Forecast — Price Target — Prediction for 2027 - TradingView
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index - markets.businessinsider.com
DBV Technologies S.A. - Via Ritzau
DBV Technologies (ENXTPA:DBV) Advances Peanut Patch With New Phase 3 Data And Infant Trial - Yahoo Finance
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
DBV Technologies Screens First Infant in THRIVE Peanut Patch Trial - HCPLive
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 - The Manila Times
Peanut patch helps allergic kids with asthma and eczema in trial - Stock Titan
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
European ADRs Slip As Nokia And Sequans Lead Declines - Finimize
DBV Technologies (NASDAQ: DBVT) ties 4,060,000 CEO PSUs to FDA milestones - Stock Titan
DBV Technologies Shareholders Approve Governance and Capital Measures - The Globe and Mail
DBV's Moment of Truth: A Patch, a Promise, and a High-Stakes Pitch - BriefGlance
DBV Technologies Announces the Results of its 2026 Combined General Meeting - markets.businessinsider.com
symbol__ Stock Quote Price and Forecast - CNN
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy - The Manila Times
DBV Technologies Announces First Participant Screened in - GlobeNewswire
Peanut-allergic babies enter THRIVE study for skin patch therapy - Stock Titan
European ADRs Tick Higher In US Trading - Finimize
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and TG Therapeutics (TGTX) - The Globe and Mail
DBVTDBV Technologies ADR Stock Price and Quote - Finviz
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Crescent Biopharma (CBIO) and Genmab (GMAB) - The Globe and Mail
Combined General Meeting of June 3, 2026 - Moomoo
European ADRs Rose Monday, With Biotech Names Leading Moves - Finimize
MPM BioImpact reports 8.8% stake in DBV Technologies (DBVT) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI), Immunic (IMUX) and Protara Therapeutics (TARA) - The Globe and Mail
Adage insiders report 22,272,884 shares in DBV Technologies (NASDAQ: DBVT) - Stock Titan
Artisan Partners (DBVT) discloses 2,219,386 ADS; 3.7% stake reported - Stock Titan
Vivo Opportunity (DBVT) holds 2.36M ADSs — 4.0% ownership disclosed - Stock Titan
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq - markets.businessinsider.com
Finanzdaten der Dbv Technologies Adr-Aktie (DBVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dbv Technologies Adr-Aktie (DBVT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| EPIC Bpifrance | Member of 10% owner group |
Dec 17 '25 |
Sale |
4.85 |
2,076,990 |
10,070,232 |
8,595,472 |
| EPIC Bpifrance | Member of 10% owner group |
Dec 18 '25 |
Sale |
4.19 |
1,292,103 |
5,413,912 |
7,303,369 |
| Mohideen Pharis | Chief Medical Officer |
Nov 20 '25 |
Sale |
2.88 |
6,496 |
18,708 |
103,153 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '25 |
Sale |
2.77 |
1,624 |
4,498 |
101,529 |
| Mohideen Pharis | Chief Medical Officer |
Jul 29 '25 |
Sale |
2.22 |
464 |
1,030 |
109,649 |
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):